Society of Hematologic Oncology (SOHO) session to highlight volasertib program Phase 2 volasertib AML program expected to begin in the coming months FOSTER CITY, Calif., Aug. 29, 2024 — Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform…
Uncategorized
Notable Labs Announces CEO Transition
Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) — Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies…
Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study
Phase 2 dosing plan, agreed with FDA, paves the way to initiate patient enrollment FOSTER CITY, Calif., July 24, 2024 (GLOBE NEWSWIRE) — Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the…
Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024
FOSTER CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) — Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced that Thomas Bock, M.D., Chief Executive Officer of Notable Labs, will participate in a fireside chat at…
Notable Labs Reports 2023 Financial Results and Provides a Business Update
FOSTER CITY, CA, April 12, 2024 – Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), reported financial results for the year ended December31, 2023 and provided a business update. “The last year has been a time of great accomplishment for Notable. We built a strong clinical validation dataset, starting with a poster presented at the…
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
Poster outlines the parameters for developing a flow-cytometry-based PPMP as a companion diagnostic to predict volasertib responders, based on a proof-of-concept study using 41 primary acute myeloid leukemia (AML) samples Plans to incorporate a dose optimization prelude to enhance patient response and tolerability also outlined in the poster FOSTER CITY, Calif., April 09, 2024 (GLOBE…
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform
FOSTER CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) — Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), today presented data related to innovations in the use of cryopreserved samples in the PPMP assay at…
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform
FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) — Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer therapies based on its Predictive Precision Medicine Platform (PPMP), today announced that the Company will present two posters related to its PPMP platform at the American Association…
Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment
Predictive Precision Medicine Platform (PPMP) utilized to enrich program for clinically responding patients and reduce the risk, time, and cost of drug development Volasertib Phase 2 trial initiation in relapsed/refractory acute myeloid leukemia anticipated in Q2 2024, and first data in Q4 2024 Relapsed/refractory acute myeloid leukemia constitutes an urgent unmet medical need with typical…
Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome
– PPMP Accurately Predicted Patient Outcomes in Fosciclopirox Phase 2a Leukemia Trial – – Predictive Results Further Advance PPMP and Corroborate Outcomes from 4 PPMP Validation Trials – – Furthers Opportunity to Accelerate PPMP Use in Front-End Drug Development – FOSTER CITY, Calif. and KANSAS CITY, Mo., Dec. 18, 2023 (GLOBE NEWSWIRE) — Notable Labs,…
